William Fricker
Keine laufenden Positionen mehr
Profil
William Fricker worked as a Controller at Immunomedics, Inc. from 2018 to 2020.
He was the Chief Financial Officer at NRX Pharmaceuticals, Inc. in 2021.
In 2022, he worked as the Chief Financial Officer at Eleison Pharmaceuticals, Inc. Mr. Fricker also held a position as VP, Global Controller & Chief Accounting Officer at J.
M.
Huber Micropowders, Inc.
Ehemalige bekannte Positionen von William Fricker
| Unternehmen | Position | Ende |
|---|---|---|
Eleison Pharmaceuticals, Inc.
 Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Finanzdirektor/CFO | 01.01.2023 |
| NRX PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 30.08.2021 |
| IMMUNOMEDICS, INC. | Comptroller/Controller/Auditor | 01.10.2020 |
J. M. Huber Micropowders, Inc.
 J. M. Huber Micropowders, Inc. Chemicals: SpecialtyProcess Industries Part of J. M. Huber Corp., J. M. Huber Micropowders, Inc. is a company that manufactures chemicals and minerals. The company is based in Edison, NJ. The CEO of the company is Matthew O'Brien. | Comptroller/Controller/Auditor | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NRX PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
J. M. Huber Micropowders, Inc.
J. M. Huber Micropowders, Inc. Chemicals: SpecialtyProcess Industries Part of J. M. Huber Corp., J. M. Huber Micropowders, Inc. is a company that manufactures chemicals and minerals. The company is based in Edison, NJ. The CEO of the company is Matthew O'Brien. | Process Industries |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Health Technology |
